NCT00354770

N-Acetyl Cysteine in Trichotillomania

A Double-Blind, Placebo-Controlled Study of N-Acetyl Cysteine in Trichotillomania

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: University of Chicago · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a 12-week, double-blind study of N-Acetyl Cysteine in the treatment of trichotillomania

Detailed description

The goal of the proposed study is to evaluate the efficacy and safety of N-Acetyl Cysteine (NAC) in trichotillomania. Forty subjects with DSM-IV trichotillomania will receive 12 weeks of double-blind NAC or placebo. The hypothesis to be tested is that NAC will be effective and well tolerated in patients with trichotillomania compared to placebo. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.

Conditions

• Trichotillomania

Interventions

Type	Name	Description
DRUG	Placebo	daily
DRUG	N-Acetyl Cysteine	600mg capsules in varying doses for 12 weeks.

Timeline

• Start date: 2006-07-01
• Primary completion: 2008-09-01
• Completion: 2008-09-01
• First posted: 2006-07-20
• Last updated: 2023-02-23
• Results posted: 2014-01-15

Locations

1 site across 1 country: United States